The protective effects of the anti-TNFα treatment on the incidence of COVID-19 symptoms reported in our study (RR = 0.50; CI 95% 0.33, 0.75) fully agree with the comments recently published about the urgent need of clinical trials of anti-TNFα therapy for COVID-19 (Feldmann et al., 2020; Robinson et al., 2020). The gene discussed is TNF; the disease is COVID-19.